PURPOSE: The aims of our study were to elucidate the role of methylation of a large panel of genes during multistage pathogenesis of bladder cancer and to correlate our findings with patient age and other clinicopathologic features. EXPERIMENTAL DESIGN: We studied the methylation status of 21 genes by quantitative methylation-specific PCR in an evaluation set of 25 tumor and 5 normal samples. Based on methylation frequency in tumors and normals in gene evaluation set, we selected 7 candidate genes and tested an independent set of 93 tumors and 26 normals. The presence or absence of methylation was evaluated for an association with cancer using cross-tabulations and chi(2) or Fisher's exact tests as appropriate. All statistical tests were two-sided. RESULTS: Most primary tumors (89 of 93, 96%) had methylation of one or more genes of independent set; 53 (57%) CCNA1, 29 (31%) MINT1, 36 (39%) CRBP, 53 (57%) CCND2, 66 (71%) PGP9.5, 60 (65%) CALCA, and 78 (84%) AIM1. Normal uroepithelium samples from 26 controls revealed no methylation of the CCNA1 and MINT1 genes, whereas methylation of CRBP, CCND2, PGP9.5, and CALCA was detected at low levels. All the 7 genes in independent set were tightly correlated with each other and 3 of these genes showed increased methylation frequencies in bladder cancer with increasing age. PGP9.5 and AIM1 methylation correlated with primary tumor invasion. CONCLUSION: Our results indicate that the methylation profile of novel genes in bladder cancers correlates with clinicopathologic features of poor prognosis and is an age-related phenomenon.
PURPOSE: The aims of our study were to elucidate the role of methylation of a large panel of genes during multistage pathogenesis of bladder cancer and to correlate our findings with patient age and other clinicopathologic features. EXPERIMENTAL DESIGN: We studied the methylation status of 21 genes by quantitative methylation-specific PCR in an evaluation set of 25 tumor and 5 normal samples. Based on methylation frequency in tumors and normals in gene evaluation set, we selected 7 candidate genes and tested an independent set of 93 tumors and 26 normals. The presence or absence of methylation was evaluated for an association with cancer using cross-tabulations and chi(2) or Fisher's exact tests as appropriate. All statistical tests were two-sided. RESULTS: Most primary tumors (89 of 93, 96%) had methylation of one or more genes of independent set; 53 (57%) CCNA1, 29 (31%) MINT1, 36 (39%) CRBP, 53 (57%) CCND2, 66 (71%) PGP9.5, 60 (65%) CALCA, and 78 (84%) AIM1. Normal uroepithelium samples from 26 controls revealed no methylation of the CCNA1 and MINT1 genes, whereas methylation of CRBP, CCND2, PGP9.5, and CALCA was detected at low levels. All the 7 genes in independent set were tightly correlated with each other and 3 of these genes showed increased methylation frequencies in bladder cancer with increasing age. PGP9.5 and AIM1 methylation correlated with primary tumor invasion. CONCLUSION: Our results indicate that the methylation profile of novel genes in bladder cancers correlates with clinicopathologic features of poor prognosis and is an age-related phenomenon.
Authors: R Maruyama; S Toyooka; K O Toyooka; K Harada; A K Virmani; S Zöchbauer-Müller; A J Farinas; F Vakar-Lopez; J D Minna; A Sagalowsky; B Czerniak; A F Gazdar Journal: Cancer Res Date: 2001-12-15 Impact factor: 12.701
Authors: Yu Mi Lee; Ji Yun Lee; Mi Jin Kim; Han Ik Bae; Jae Yong Park; Sang Geol Kim; Dong Sun Kim Journal: Cancer Sci Date: 2006-09-12 Impact factor: 6.716
Authors: C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307
Authors: Arvind K Virmani; Jeffrey A Tsou; Kimberly D Siegmund; Linda Y C Shen; Tiffany I Long; Peter W Laird; Adi F Gazdar; Ite A Laird-Offringa Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-03 Impact factor: 4.254
Authors: Mohammad Obaidul Hoque; Shahnaz Begum; Mariana Brait; Carmen Jeronimo; Marianna Zahurak; Kimberly Laskie Ostrow; Eli Rosenbaum; Bruce Trock; William H Westra; Mark Schoenberg; Steven N Goodman; David Sidransky Journal: J Urol Date: 2007-12-20 Impact factor: 7.450
Authors: In-Seon Choi; Kevin Yu; Jayoung Kim; Erika De Guzman; Daniel J Weisenberger; Shirley Oghamian; Hee Ju Kim; Kyung Hwa Lee; Cindy Carroll; Binh N Trinh; Myungjin Kim; Sahar Houshdaran; Peter W Laird; Peter A Jones; David Warburton; Gangning Liang; Chester J Koh Journal: Urology Date: 2013-07 Impact factor: 2.649
Authors: Myriam Loyo; Mariana Brait; Myoung S Kim; Kimberly L Ostrow; Chunfa C Jie; Alice Y Chuang; Joseph A Califano; Nanette J Liégeois; Shahnaz Begum; William H Westra; Mohammad O Hoque; Qian Tao; David Sidransky Journal: Int J Cancer Date: 2011-03-15 Impact factor: 7.396
Authors: Eli Rosenbaum; Shahnaz Begum; Mariana Brait; Marianna Zahurak; Leonel Maldonado; Leslie A Mangold; Mario A Eisenberger; Jonathan I Epstein; Alan W Partin; David Sidransky; Mohammad O Hoque Journal: Prostate Date: 2011-11-29 Impact factor: 4.104
Authors: Rodrigo García-Baquero; Patricia Puerta; Manuel Beltran; Miguel Alvarez-Mújica; Jose Luis Alvarez-Ossorio; Marta Sánchez-Carbayo Journal: Tumour Biol Date: 2014-02-28
Authors: Mariana Brait; Jean G Ford; Srinivas Papaiahgari; Mary A Garza; Jin I Lee; Myriam Loyo; Leonel Maldonado; Shahnaz Begum; Lee McCaffrey; Mollie Howerton; David Sidransky; Mark R Emerson; Saifuddin Ahmed; Carla D Williams; Mohammad Obaidul Hoque Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-10-27 Impact factor: 4.254